Literature DB >> 16455454

Combined hepatic and inferior vena cava resection for colorectal metastases.

Scott T Johnson1, Maurice Blitz, Norman Kneteman, David Bigam.   

Abstract

Surgical resection continues to offer the only hope for cure of colorectal cancer metastatic to the liver. Tumor involvement of the vena cava is often viewed as a contraindication to surgical resection. Whereas proven technically feasible, the survival advantages of en bloc liver and vena cava resection remain unclear. We reviewed all patients at a tertiary care center who had resection of colorectal liver metastases, including those with vena cava resections. Eleven patients had en bloc liver and vena cava resection between 1988 and 2002; during the same time period, 97 patients underwent isolated liver resection. There were no perioperative deaths in the 11 patients. All resections had negative histological margins. Mean follow-up was 33 months from the date of surgery. Median disease-free survival of the group having caval resections was 9 months, whereas median survival was 34 months. When compared to the cohort of isolated hepatic resections, the group undergoing caval resections experienced a significantly reduced disease-free survival of 18.6 vs. 9.1 months, respectively (P = 0.03); however, there was no difference in overall survival between the two groups at 55.2 vs. 34.3 months, respectively (P = 0.20). Colorectal liver metastases involving the vena cava should be considered for surgical resection.

Entities:  

Mesh:

Year:  2006        PMID: 16455454     DOI: 10.1016/j.gassur.2005.09.012

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  19 in total

1.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

2.  Resection of the inferior vena cava for hepatic malignancy.

Authors:  A W Hemming; M R Langham; A I Reed; W J van der Werf; R J Howard
Journal:  Am Surg       Date:  2001-11       Impact factor: 0.688

3.  Benefits and safety of hepatic resection for colorectal metastases.

Authors:  K E Harmon; J A Ryan; T R Biehl; F T Lee
Journal:  Am J Surg       Date:  1999-05       Impact factor: 2.565

4.  Radiofrequency ablation followed by resection of malignant liver tumors.

Authors:  C H Scudamore; S I Lee; E J Patterson; A K Buczkowski; L V July; S W Chung; A R Buckley; S G Ho; D A Owen
Journal:  Am J Surg       Date:  1999-05       Impact factor: 2.565

5.  Surgical experience with hepatic colorectal metastasis.

Authors:  A L Bradley; W C Chapman; J K Wright; J W Marsh; S Geevarghese; K T Blair; C W Pinson
Journal:  Am Surg       Date:  1999-06       Impact factor: 0.688

6.  Resection of hepatic metastases of colorectal carcinoma: 20 years' experience.

Authors:  S Nakamura; S Suzuki; H Konno
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

7.  Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.

Authors:  S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

8.  Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors.

Authors:  David S K Lu; Steven S Raman; Piyaporn Limanond; Donya Aziz; James Economou; Ronald Busuttil; James Sayre
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Hepatic resection with reconstruction of the inferior vena cava or hepatic venous confluence for metastatic liver tumor from colorectal cancer.

Authors:  Taku Aoki; Yasuhiko Sugawara; Hiroshi Imamura; Yasuji Seyama; Masami Minagawa; Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Am Coll Surg       Date:  2004-03       Impact factor: 6.113

View more
  5 in total

Review 1.  Evolving role of vascular resection and reconstruction in hepatic surgery for malignancy.

Authors:  Kristin L Mekeel; Alan W Hemming
Journal:  Hepat Oncol       Date:  2013-12-20

Review 2.  Repeat hepatectomy with inferior vena cava re-resection for colorectal liver metastases: case report and review of the literature.

Authors:  Gabriele Marangoni; Abdul Hakeem; Atif Khan; Olorunda Rotimi; J Peter Lodge
Journal:  Surg Today       Date:  2014-12-04       Impact factor: 2.549

3.  Hepatic colorectal metastases involving infra-hepatic inferior vena cava in high risk patients for extended resection: an alternative method for achieving radical resection in patient with borderline liver remnant.

Authors:  Francesco Polistina; Alessandro Fabbri; Giovanni Ambrosino
Journal:  Indian J Surg       Date:  2012-07-06       Impact factor: 0.656

4.  Modified ante situm liver resection without use of cold perfusion nor veno-venous bypass for treatment of hepatic lesions infiltrating the hepatocaval confluence.

Authors:  F Oldhafer; K I Ringe; K Timrott; M Kleine; O Beetz; W Ramackers; S Cammann; J Klempnauer; F W R Vondran; H Bektas
Journal:  Langenbecks Arch Surg       Date:  2018-02-22       Impact factor: 3.445

Review 5.  The impact of multivisceral liver resection on short- and long-term outcomes of patients with colorectal liver metastasis: A systematic review and meta-analysis.

Authors:  Sérgio Silveira Júnior; Francisco Tustumi; Daniel de Paiva Magalhães; Vagner Birk Jeismann; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Fabricio Ferreira Coelho; Paulo Herman
Journal:  Clinics (Sao Paulo)       Date:  2022-09-16       Impact factor: 2.898

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.